Ketorolac is a nonsteroidal anti-inflammatory, or NSAID, drug used to treat moderately severe to acute pain.
Fresenius Kabi said it found the recalled lots contain carbon, silicon, oxygen and polyamides.
Giving patients the recalled drugs could cause serious, life-threatening effects, such as blood clots and lung tissue scarring.
Fresenius Kabi told its customers to immediately discontinue use of the affected lots and return them to the drugmaker.
The company didn’t say if it’s received any adverse event reports related to the recall.
Read the full news release here.
More articles on pharmacy:
Largest hydroxychloroquine study to date finds no benefit for COVID-19
NIH panel releases COVID-19 treatment, pharmaceutical intervention guidelines
How 13 drugmakers have responded to the COVID-19 pandemic
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
